TAMPA, Florida, May 18, 2010 /PRNewswire/ —
– Amidst Industry Unrest due to Drug Pricing Benchmark Upheaval,
Gold Standard/Elsevier to Continue Publishing AWP and Other Pricing
Standards
Gold Standard/Elsevier, publisher of drug information databases
and decision support solutions, has announced its commitment to
continue publishing transparent drug pricing information, including
average wholesale price (AWP) and all other current and future
pricing benchmarks. This announcement comes amidst statements by
other drug database suppliers indicating they will discontinue
publishing AWP in 2011.
“Gold Standard reports all drug pricing standards utilized and
required within the industry, and we intend to continue doing so,”
stated Kay Morgan, Senior Vice
President, Drug Product and Industry Standards Research and
Compliance for Gold Standard/Elsevier. “We understand the
frustrations felt by those who rely on AWP and expect stability and
dependability from their drug databases. We look forward to
providing a reliable and flexible resource for pricing
industry-wide, including AWP and any new benchmarks, through our
Alchemy drug database and ProspectoRx pricing analysis tool.”
Gold Standard/Elsevier supports transparent price benchmarks for
payers (health plans, patients, government agencies and employers),
pharmacies and other providers for prescription drugs. The company
publishes reported and calculated drug prices that are clearly
distinguished within the database, and adheres to strict internal
policies for populating reported versus calculated pricing fields.
Drug company reported prices of AWP, WAC (wholesale acquisition
cost), CMS FUL (Federal Upper Limit), and Direct Price are included
in Gold Sta
‘/>”/>
